This Phase 2 study is testing a new oral medication called MORF-057 for adults with moderately to severely active Crohn's disease (CD). MORF-057 works by selectively blocking integrin α4β7, which is involved in inflammation. The study will compare MORF-057 to a placebo (an inactive pill that looks the same) to see how well it works and if it's safe. Researchers will measure how many participants show an endoscopic response (improvement seen during an endoscopy) after 14 weeks. You might be able to join if you are between 18 and 85 years old, have had Crohn's symptoms for at least 90 days, and your current treatments haven't worked well enough. The study is currently recruiting about 385 participants.

Study design

This is a Phase 2, randomized, double-blind, placebo-controlled study involving about 385 participants. It will compare three different doses of MORF-057 to a placebo.

What's involved

Participants will receive either MORF-057 or placebo for 14 weeks, followed by open-label MORF-057 for 38 weeks. There is also an option to continue treatment for another 52 weeks.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed during the 14-week induction period, the 38-week maintenance period, and potentially a 52-week long-term extension.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.